Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)

NCT02009865 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02009865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02009865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2013
Completion date
December 23, 2014
Enrollment
379 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia